logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10898469 B1

PDFFull Text
Date of Patent:
Jan. 26, 2021

Filed:

Feb. 23, 2017

Imidazolylamide derivative

Applicant:

Sumitomo Dainippon Pharma Co., Ltd., Osaka, JP;

Inventors:

Hitoshi Ban, Osaka, JP;

Manabu Kusagi, Osaka, JP;

Shingo Tojo, Osaka, JP;

Tsuguteru Otsubo, Osaka, JP;

Eiji Sugaru, Osaka, JP;

Hiroki Yamaguchi, Osaka, JP;

Nobuyuki Sawada, Fujisawa, JP;

Chiang Jia Li, Cambridge, MA (US);

Assignee:

Sumitomo Dainippon Pharma Co., Ltd., Osaka, JP;

Attorney:

Fish & Richardson P.C.

Primary Examiner:

David K O'Dell

Int. Cl.
CPC ...
A61K 31/4178 (2006.01); C07D 417/14 (2006.01); C07D 403/12 (2006.01); C07D 401/06 (2006.01); C07D 233/90 (2006.01); C07D 403/10 (2006.01); C07D 405/06 (2006.01); C07D 487/04 (2006.01); C07D 413/12 (2006.01); C07D 409/12 (2006.01); C07D 233/88 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07D 417/12 (2006.01); C07D 495/04 (2006.01); C07D 409/06 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); A61K 31/4174 (2006.01); A61K 31/4709 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61P 35/02 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/454 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 31/4174 (2013.01); A61K 31/437 (2013.01); A61K 31/4365 (2013.01); A61K 31/4375 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07D 233/88 (2013.01); C07D 233/90 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 409/06 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01);
Abstract

The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Qrepresents a Caryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R, independently when multiple, represent(s) a halogen atom or the like; Rand Rindependently represent a hydrogen atom or the like; Wrepresents a Calkylene group (said group may be substituted by 1-3 fluorine atoms or Ccycloalkyls); Wrepresents —NRC(O)— or the like (where Rrepresents a hydrogen atom or Calkyl group); and ring Qrepresents a Carylgroup or the like]

Find Patent Forward Citations

Loading…